PSMA-targeted radioligand therapy improves survival in patients with mCRPC
10 Oct 2025
byDr. Michael Kam, Specialist in Clinical Oncology, Hong Kong
A 63-year-old male with hypertension, hyperlipidaemia and diabetes was diagnosed with metastatic prostate cancer with lumbar spine metastases in 2018. He initially presented with lower urinary tract symptoms and markedly elevated prostate-specific antigen (PSA) of up to 85.3 ng/mL. He was started on luteinizing hormone–releasing hormone (LHRH) antagonist as androgen deprivation therapy (ADT) with good response of PSA drop to 13.4 mg/mL.
